Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom (DXCM) Stock Hits 52-Week High: More Room to Grow?

Etsy

DexCom is making continuous glucose monitoring technology more widespread. Etsy is highly successful in its small corner of the large e-commerce industry.

2 Growth Stocks That Could Double in 5 Years

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call to review the company's second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time

DexCom's (DXCM) G7 CGM System's latest approval by Health Canada is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

DexCom's (DXCM) G7 CGM System Gets Nod From Health Canada

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older. Diabetes is a complex and burdensome condition affecting more than 3 million Canadians6. It requires around-the-clock management of glucose levels and da.

Dexcom G7 Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System With Unmatched Accuracy Coming to Canadians

Enphase Energy

Fortinet

ServiceNow

Palo Alto Networks

Paycom Software

Insulet

SolarEdge Technologies

“Can tech keep up the pace?” is a burning question for many with regards to a sector that helped drive the S&P 500 SPX, +0.12% to its best first half since 2019.

These stocks could be the next Magnificent Seven market leaders, says Goldman Sachs

From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached a key level of support. DXCM recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

DexCom (DXCM) Just Flashed Golden Cross Signal: Do You Buy?

DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.

Looking for a Growth Stock? 3 Reasons Why DexCom (DXCM) is a Solid Choice

Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.

Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View

Dexcom's revenue could reach $5 billion in 2025, the company said Friday as it announced a new CGM device. Dexcom stock could soar again.

Dexcom, A Top 2% Stock, Raises 2025 Outlook Amid 'Rapidly' Expanding Diabetes Market

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #ADA--Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More.

Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--Dexcom Updates Long-Range Financial Targets.

Dexcom Updates Long-Range Financial Targets

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

You generally associate Super Bowl commercials with products made by PepsiCo Inc. NYSE: PEP or the Coca-Cola Co. NYSE: KO, but earlier this year, glucose-monitoring geat maker DexCom Inc. NASDAQ: DXCM forked over some bucks to advertise its G7 sensors.

DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth

LONDON--(BUSINESS WIRE)--Dexcom G6 is now the first and only CGM to connect with the Omnipod® 5 Automated Insulin Delivery System in the United Kingdom.

Dexcom G6 Strengthens Its Position as World's Most Connected CGM System

Chipotle

Hyatt Hotels

The Dow Jones Industrial Average rallied 428 points Thursday, hitting a 2023 high. Chipotle is one of the stock market leaders to watch.

Dow Up 428 Points As Stocks Hits 2023 Highs; Chipotle, Dexcom, Hyatt Near Buy Points

As diabetes leader Dexcom pumps up 113% growth and a collaboration with Nick Jonas, Dexcom stock pokes at a new buy zone.

Spotlight Shines On Super Bowl, Chip Stocks And Nick Jonas

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations from Dexcom management highlighting the company's market opportunities, business strategy, innovation efforts, and long-term financial outlook. Links to a live webcast of the event will be available on the Dexcom Investor Relations website at investors.dexcom.com and will b.

Dexcom to Host Investor Day on June 23, 2023

Activision Blizzard

Axon Enterprise

Entegris

Microsoft

Sarepta Therapeutics

Visa

Sands Capital Management recently disclosed its 13F portfolio updates for the first quarter of 2023, which ended on March 31.

Frank Sands' Top 1st-Quarter Buys

Fiverr

The gig economy and diabetes care each represent rapidly-expanding total addressable markets. Fiverr isn't yet profitable, but its bottom line is improving as it grows its revenue and take rate.

Have $1,500? 2 Top Growth Stocks to Buy and Hold for the Long Haul

Diabetes care and e-commerce are explosive industries set to see tremendous growth over the coming decade. DexCom is rolling out its latest product, and a new Medicare ruling should expand its total addressable market.

2 Incredible Growth Stocks to Buy Before the Next Bull Market

Alphabet

Since early 2022, everyday investors and Wall Street's brightest billionaire money managers have flocked to stocks enacting splits. The sustained competitive advantages offered by three stock-split stocks made them popular buys during the first quarter.

3 Stock-Split Stocks Billionaires Can't Stop Buying

Apple

DraftKings

Li Auto Inc.

NVIDIA

Spotify

Tractor Supply

Want to ride the hot hand of the market? Consider these nine momentum stocks that are climbing the charts this year.

9 Momentum Stocks to Buy Now

Abbott Labs

CNBC spoke with both Abbott and Dexcom about the technology inside continuous glucose monitors and how they see the technology expanding.

How Dexcom and Abbott are moving beyond diabetes with blood sugar monitoring

Airbnb

Concerns about the economy linger among investors, but some companies could show resilience. DexCom is serving a constant and growing need with its continuous glucose monitoring devices.

News for DexCom Stock (DXCM)